Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance

Clinical Infectious Diseases

Volumn 30, Issue 1, 2000, Pages 71-77

  Fiore, Anthony E ^a,f   Moroney, John F ^a   Farley, Monica M ^c   Harrison, Lee H ^d   Patterson, Jan E ^e   Jorgensen, James H ^e   Cetron, Martin ^a   Kolczak, Margarette S ^b   Breiman, Robert F ^a   Schuchat, Anne ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; PENICILLIN G; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MENINGITIS; BACTERIUM ISOLATE; CHILD; HOSPITALIZATION; HUMAN; INTUBATION; MAJOR CLINICAL STUDY; MORTALITY; OXYGEN BREATHING; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN;

EID: 0033956697     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313606     Document Type: Article

References (35)

1. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337:970-6.
2. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271:1831-5.
3. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system. J Infect Dis 1996; 174:986-93.
4. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481-6.
5. Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 1991; 10:871-3.
6. John CC. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994; 18:188-93.
7. Lonks JR, Durkin MR, Meyerhoff AN, Medeiros AA. Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae. N Engl J Med 1995; 332:893-4.
8. Guibert M, Chahime H, Petit J, Odievre M, Labrune P. Failure of cefotaxime treatment in two children with meningitis caused by highly penicillin-resistant Streptococcus pneumoniae. Acta Paediatr 1995; 84:831-3.
9. Greene GS, Demasi R. Case report: penicillin-resistant pneumococcal meningitis: navigating a therapeutic minefield. Am J Med Sci 1996; 311:180-5.
10. Pachecho TR, Cooper CK, Hardy DJ, Betts RF, Bonnez W. Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitis. Am J Med 1997; 102:303-5.
11. Catalan MJ, Fernandez JM, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae meningitis. Clin Infect Dis 1994; 18:766-9.
12. Sloas MM, Barrett FF, Chesney, et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992; 11:662-6.
13. Steinberg T, Rachmel A, Samra Z, Ashkenazi S. Penicillin-resistant pneumococcal meningitis in Israel. Isr J Med Sci 1997; 33:757-9.
14. American Academy of Pediatrics. Therapy for children for invasive pneumococcal infections. Pediatrics 1997; 99:289-99.
15. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708-16.
16. Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994; 38:918-23.
17. Freidland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995; 14:885-90.
18. Choi E-H, Lee H-J. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998; 26:1346-54.
19. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
20. Arditi M, Mason EO, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998; 102:1087-97.
21. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 4th ed. NCCLS document no. M7-A4. Wayne, PA: NCCLS, 1997.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
23. Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16:1110-6.
24. Friedland IR, Klugman KP. Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high-dosage cefotaxime. Antimicrob Agents Chemother 1997; 41:1888-91.
25. Bradley JS, Kaplan SL, Klugman KP, Leggiadro RJ. Consensus: management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin. Pediatr Infect Dis J 1995; 14:1037-41.
26. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am 1997; 11:867-74.
27. Paris MM, Ramilo O, McCracken GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39:2171-5.
28. Bohr V, Rasmussen N, Hanson B. Pneumococcal meningitis: an evaluation of prognostic factors in 164 cases based on mortality and a study of lasting sequelae. J Infect 1985; 10:143-57.
29. Weiss W, Figueroa W, Shapiro WH, Flippin HF. Prognostic factors in pneumococcal meningitis. Arch Intern Med 1967; 120:517-20.
30. Lebel MH, Freij BJ, Syrogiannopolous GA, et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319:964-71.
31. Tunkel AR, Scheld WM. Acute bacterial meningitis. Lancet 1995; 346:1675-80.
32. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA 1997; 278:925-31.
33. Townsend GC, Scheld WM. The use of corticosteroids in the management of bacterial meningitis in adults. J Antimicrob Chemother 1996; 37:1051-61.
34. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46(RR-8):1-24.
35. Black SB, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial. In: Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.